JZL195

Research use only, not for human use.

JZL195 is a selective and efficacious dual FAAH/MAGL inhibitor.

JZL195 is a potent and selective dual inhibitor of FAAH and monacylglycerol lipase (MAGL). JZL195 has greater anti-allodynic efficacy than selective FAAH, or MAGL inhibitors, plus a greater therapeutic window than a cannabinoid receptor agonist. JZL195 may have greater potential in alleviating neuropathic pain, compared to selective FAAH and MAGL inhibitors, or cannabinoid receptor agonists.

JZL195 produces near-complete blockade of FP-Rh labeling of both mouse brain FAAH and MAGL at concentrations as low as 100 nM (IC50 values of 13 and 19 nM, respectively).JZL195 inhibits rat and human FAAH and MAGL enzymes with IC50 values in the range of ≈10-100 nM based on competitive ABPP assays.

JZL195 (20 mg/kg; i.p.) produces an antinociceptive response in the tail immersion assay. Animal Model:Male C57BL/6J miceDosage:20 mg/kg Administration:Intraperitoneal injection Result:Produced a much greater antinociceptive response in the tail immersion assay compared with inhibitors of either FAAH or MAGL alone.

JZL195 | JZL-195 | JZL 195

Others

Other Targets

FAAH| MAGL

Inflammation/Immunology

——

1210004-12-8

433.46

C24H23N3O5

>98% (HPLC)

DMSO : ≥ 42 mg/mL. 96.89 mM

[O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cc(Oc4ccccc4)ccc3)CC2)cc1

4-nitrophenyl 4-(3-phenoxybenzyl)piperazine-1-carboxylate

(-20℃)

With Ice Pack

≥ 2 years